EFSA has updated its safety assessment of the food additive titanium dioxide (E 171), following a request by the European Commission in March 2020. 

In recent years, titanium dioxide (TiO2) has gained immense popularity across various industries due to its excellent properties, such as high opacity, brightness, and ultraviolet light absorption. As a result, the demand for titanium dioxide has increased significantly, prompting a surge in the number of manufacturers hoping to capitalize on this booming market. While quality remains a priority, cost-effectiveness has emerged as a crucial factor for consumers, leading to a growing interest in cheap titanium dioxide manufacturers.

For a mini-review published in the journal Particle and Fibre Technology in 2021, scientists wanted to evaluate whether Ti02 particles contributed to the development and/or exacerbation of irritable bowel disease, and whether they altered the four elements of intestinal barrier function: the intestinal microbiota, the immune system, the mucus layer, and the epithelium. The breakdown of these four elements can contribute to autoimmune, neurological, inflammatory, infectious, and metabolic diseases. Following their review, the researchers concluded: “Data indicate that TiO2 is able to alter the four compartments of IBF and to induce a low-grade intestinal inflammation associated or not with pre-neoplastic lesions.”